Daiwa Securities Group Inc. Has $3.46 Million Holdings in Repligen Co. (NASDAQ:RGEN)

Daiwa Securities Group Inc. raised its position in Repligen Co. (NASDAQ:RGEN) by 29.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,046 shares of the biotechnology company’s stock after purchasing an additional 5,466 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Repligen were worth $3,461,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of RGEN. Champlain Investment Partners LLC lifted its position in Repligen by 149.0% during the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock worth $211,464,000 after buying an additional 850,345 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Repligen during the fourth quarter worth about $52,492,000. Allspring Global Investments Holdings LLC boosted its position in Repligen by 79.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company’s stock valued at $65,395,000 after purchasing an additional 203,011 shares during the last quarter. DF Dent & Co. Inc. grew its stake in Repligen by 31.0% in the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock valued at $87,852,000 after purchasing an additional 139,615 shares in the last quarter. Finally, Two Sigma Advisers LP increased its position in shares of Repligen by 421.9% during the 3rd quarter. Two Sigma Advisers LP now owns 126,300 shares of the biotechnology company’s stock worth $18,796,000 after purchasing an additional 102,100 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have issued reports on RGEN shares. HC Wainwright restated a “buy” rating and issued a $180.00 price objective on shares of Repligen in a research note on Friday, February 21st. JPMorgan Chase & Co. increased their price target on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. TD Cowen began coverage on shares of Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 price objective for the company. Canaccord Genuity Group started coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price for the company. Finally, Canaccord Genuity Group lifted their target price on shares of Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $181.00.

Repligen Trading Down 2.0 %

Shares of RGEN stock opened at $142.44 on Friday. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $200.23. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The company has a 50 day moving average of $157.17 and a 200-day moving average of $148.45. The firm has a market cap of $7.98 billion, a P/E ratio of -279.29, a PEG ratio of 4.54 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. The company had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. Sell-side analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.